Spain's pharma industry reinforces commitment for public-private collaboration in research
Latest figures show that the Spanish pharmaceutical industry invested 382 million euros ($431 million) in contracts with the National Health system during 2014, maintaining once again its leading position in the private sector as far as public-private collaboration in Spain is concerned.
The latter was highlighted last week by trade group Farmaindustria’s director general, Humberto Arnés, during the opening session of the IX Annual Conference of Biomedical Research Technological Platforms: Innovative Medicines, Nanomedicines, Healthcare Technology and Biotechnological markets, which is held today and tomorrow in Barcelona. Under the title The New Challenges In Biomedical Research, this event, which brought together around 300 scientists and researchers, has earned its place as a reference in biomedical research, since it allows the diffusion of the most recent national and international initiatives in public-private collaboration in this area.
New regulatory framework for clinical trials
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze